Brand Name :
Tysabri, Tyruko
Synonyms :
natalizumab, natalizumab-sztn
Class :
Multiple Sclerosis Treatments; Inflammatory Bowel Disease Agents; Integrin Blockers, Monoclonal Antibodies, Integrin Blockers
Dosage forms & Strengths:
Adult:
Injectable solution:
300 mg/15 ml
300
mg
Intravenous (IV)
once a month
Solution
Note:
Indicated for the treatment in individuals with relapsing forms of multiple sclerosis, as monotherapy which encompass clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
300
mg
Intravenous (IV)
once a month
Solution
Safety and efficacy are not seen in pediatrics
Refer to adult dosing
may increase the toxic effect
may increase the risk or severity of adverse effects when combined
immunosuppressants increase the effect of immunosuppression of natalizumab
immunosuppressants increase the effect of immunosuppression of natalizumab
immunosuppressants increase the effect of immunosuppression of natalizumab
immunosuppressants increase the effect of immunosuppression of natalizumab
immunosuppressants increase the effect of immunosuppression of natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
It may enhance the effect when combined with beclomethasone, inhaled by immunosuppressive effects
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with natalizumab
natalizumab: they may increase the immunosuppressive effect of immunostimulants
natalizumab: they may increase the immunosuppressive effect of immunostimulants
natalizumab: they may increase the immunosuppressive effect of immunostimulants
natalizumab: they may increase the immunosuppressive effect of immunostimulants
natalizumab: they may increase the immunosuppressive effect of immunostimulants
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when natalizumab and melphalan combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection
The risk of infection is enhanced due to increased immunosuppressive effects of natalizumab.
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
oncologic agents may enhance the immunosuppressive effects of natalizumab
in combination with ofatumumab, natalizumab increases the risk of adverse events
when both drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
may increase the immunosuppressive effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may decrease the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
combination may enhance the immunosuppressive effect and lead to serious infections
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
it may decrease the levels of serum concentration of Fosfomycin
it may decrease the levels of serum concentration of Sirolimus
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
hydrocodone/chlorpheniramine/pseudoephedrine
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effects of opioid agonists
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of opioid agonists
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of anticholinergic agents
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Opioid Agonists
buprenorphine,long-acting injection
may decrease the therapeutic effect of Opioid Agonists
Gastrointestinal agents may lower the serum levels of the antibiotic fosfomycin
acetaminophen/doxylamine/dextromethorphan
may decrease the therapeutic effect of anticholinergic Agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
1-10%:
Fatigue
Diarrhea
Urinary urgency/frequency
Sinusitis
Vaginal infections
Arthralgia
Cough
Viral infection
Dermatitis
Pharyngolaryngeal pain
Peripheral edema
Rash
Dysmenorrhea
Skin laceration
Aphthous stomatitis
Amenorrhea
Ovarian cyst
Somnolence
Thermal burn
Dry skin
Vertigo
Dyspepsia
Irregular menstruation
Urinary incontinence
Toothache
Pruritus
Lower abdominal pain
Constipation
Vaginal infections
Limb injury
Viral infections
Urinary tract infections
Flatulence
Night sweats
Natalizumab is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
No adequate data is available regarding the usage of the drug during pregnancy.
Breastfeeding warnings:
The drug is secreted in breast milk. No data is available regarding the drug’s effect on the infant during breastfeeding.
Pregnancy category: